IP Library › Granted Patent US 9,259,429
Granted Patent B2
US 9,259,429 · App. 14/463,034 · Granted Feb 16, 2016

Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Inventors: Jeffrey L. Edelman (Irvine, CA); Kelly M. Harrison (Harker Heights, TX)
Assignee: Allergan, Inc.
A61K31/573A61K9/0048A61K9/0051A61K9/1647A61K31/56A61K31/728A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,259,429
App. No.
14/463,034
Granted
Feb 16, 2016
Kind
B2
Abstract

Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.

Claims (17)

1. A method of treating macular edema of a mammalian eye comprising periocular administration of a composition comprising a therapeutically effective amount of hyaluronic acid and a glucocorticoid derivative comprising an acyl group linked to C17 via an ester linkage.

2. The method of claim 1 , wherein the macular edema is cystoid macular edema.

3. The method of claim 1 , wherein the macular edema is diabetic macular edema.

4. The method of claim 1 , wherein the periocular administration is to an area of the eye selected from the group consisting of a retrobulbar region, a subconjunctival region, a subtenon region, a suprachoroidal region, a suprachoroidal space, and a intrascleral region.

5. The method of claim 4 wherein the periocular administration is to a suprachoroidal region or suprachoroidal space.

6. The method of claim 1 , wherein the glucocorticoid derivative has a lipophilicity greater than 2.53.

7. The method of claim 1 , wherein the glucocorticoid derivative has a lipophilicity greater than about 3.5.

8. The method of claim 1 , wherein the glucocorticoid derivative has a lipophilicity greater than about 4.0.

9. The method of claim 1 , wherein the acyl group is selected from the group consisting of an acetyl, butyryl, valeryl, propionyl, furoyl, and benzoyl group.

10. The method of claim 1 , wherein the periocular administration is performed using an injection device.

11. The method of claim 1 , wherein the glucocorticoid derivative is beclomethasone dipropionate.

12. A method of treating diabetic macular edema of a mammalian eye comprising administration to the suprachoroidal space of the eye a composition comprising a therapeutically effective amount of hyaluronic acid and a glucocorticoid derivative comprising an acyl group linked to C17 via an ester linkage.

13. The method of claim 12 , wherein the glucocorticoid derivative is beclomethasone dipropionate.

14. A method of treating macular edema of a mammalian eye comprising administration to the suprachoroidal space of the eye a composition comprising a therapeutically effective amount of a glucocorticoid derivative and a polymeric component, wherein the polymeric component is selected from the group consisting of methylcellulose, carboxymethylcellulose, hydroxymethylcellulose hydroxypropylcellulose, hydroxyethylcellulose, ethyl cellulose, hyaluronic acid, poly(lactide-co-glycolide) PLGA, poly-lactic acid (PLA), poly-glycolic acid (PGA), polyesters, poly(orthoester), poly(phosphazine), poly(phosphate ester), polycaprolactones, gelatin, collagen and combinations thereof, and wherein the glucocorticoid derivative comprises an acyl group linked to C17 via an ester linkage.

15. The method of claim 14 , wherein the glucocorticoid derivative is beclomethasone dipropionate.

16. The method of claim 14 , wherein the periocular administration is performed using an injection device.

17. The method of claim 14 , wherein the macular edema is cystoid macular edema or diabetic macular edema.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2014
From: EDELMAN, JEFFREY L.; HARRISON, KELLY M.
To: ALLERGAN, INC.
Reel/Frame 033563/0747 →
Continuity (4)
Continuation 13299215 · Nov 17, 2011
Division 11550642 · Oct 18, 2006
Provisional Application 60728209 · Oct 18, 2005
Related Publication 20140357609A1 · Dec 4, 2014